Literature DB >> 23940478

Review of the top 5 cardiology studies of 2011-12.

Arden R Barry1, Rosaleen Boswell, Ernest H Law, Dylan M Pollmann, Mohamed A Omar, Margaret L Ackman.   

Abstract

Year:  2013        PMID: 23940478      PMCID: PMC3734909          DOI: 10.1177/1715163513492498

Source DB:  PubMed          Journal:  Can Pharm J (Ott)        ISSN: 1715-1635


× No keyword cloud information.
  11 in total

1.  Rivaroxaban in patients with a recent acute coronary syndrome.

Authors:  Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

3.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Authors:  Manesh R Patel; Kenneth W Mahaffey; Jyotsna Garg; Guohua Pan; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Jonathan P Piccini; Richard C Becker; Christopher C Nessel; John F Paolini; Scott D Berkowitz; Keith A A Fox; Robert M Califf
Journal:  N Engl J Med       Date:  2011-08-10       Impact factor: 91.245

Review 4.  The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care.

Authors:  Robert S McKelvie; Gordon W Moe; Anson Cheung; Jeannine Costigan; Anique Ducharme; Estrellita Estrella-Holder; Justin A Ezekowitz; John Floras; Nadia Giannetti; Adam Grzeslo; Karen Harkness; George A Heckman; Jonathan G Howlett; Simon Kouz; Kori Leblanc; Elizabeth Mann; Eileen O'Meara; Miroslav Rajda; Vivek Rao; Jessica Simon; Elizabeth Swiggum; Shelley Zieroth; J Malcolm O Arnold; Tom Ashton; Michel D'Astous; Paul Dorian; Haissam Haddad; Debra L Isaac; Marie-Hélène Leblanc; Peter Liu; Bruce Sussex; Heather J Ross
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

5.  Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.

Authors:  S Connolly; J Pogue; R Hart; M Pfeffer; S Hohnloser; S Chrolavicius; M Pfeffer; S Hohnloser; S Yusuf
Journal:  Lancet       Date:  2006-06-10       Impact factor: 79.321

6.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

7.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

8.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

9.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

10.  Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study.

Authors:  Jonas Bjerring Olesen; Gregory Y H Lip; Morten Lock Hansen; Peter Riis Hansen; Janne Schurmann Tolstrup; Jesper Lindhardsen; Christian Selmer; Ole Ahlehoff; Anne-Marie Schjerning Olsen; Gunnar Hilmar Gislason; Christian Torp-Pedersen
Journal:  BMJ       Date:  2011-01-31
View more
  2 in total

Review 1.  Review of the top 5 cardiology studies of 2013-14.

Authors:  Arden R Barry; Jade E Basaraba; Jennifer L Bong; Chloe L McMillan; Mohamed A Omar; Dylan M Pollmann; Margaret L Ackman
Journal:  Can Pharm J (Ott)       Date:  2015-11

2.  Review of the top 5 cardiology studies of 2015-16.

Authors:  Arden R Barry; Hazal E Babadagli; Jade E Basaraba; Rosaleen Boswell; June W Chen; Mohamed A Omar; Dylan M Pollmann; Jian Song Zhou; Margaret L Ackman
Journal:  Can Pharm J (Ott)       Date:  2017-09-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.